Evommune Presents Full Phase 2 Data for Oral Mrgprx2 Inhibitor Evo756 in Chronic Inducible Urticaria During Late-Breaker at Eadv 2025 Congress

Evommune Presents Full Phase 2 Data for Oral MRGPRX2 Inhibitor EVO756 in Chronic Inducible Urticaria During Late-Breaker at EADV 2025 Congress

Clinical responses observed in 93 percent of patients at just four weeks in either FricTest Score or Pruritus-NRS, with improvements seen as early as week oneFavorable safety and tolerability profile observed; consistent with previously disclosed Phase 1 healthy volunteer studyCIndU…

Guttman-Yassky Showcases 2 Paths to Long-Term AD Control at EADV 2025

At EADV 2025, she showcased how OX40 and JAK inhibition offer complementary approaches to long-term disease control.